Advanced Therapy Medicinal Products (ATMP) CDMO services are becoming central to the translation of cell therapies, gene therapies, tissue-engineered products, and combined advanced therapies from clinical development to regulated commercial supply. Demand is being shaped by the scientific complexity of autologous and allogeneic platforms, viral and non-viral vector production, plasmid DNA supply, aseptic fill-finish, potency testing, comparability, chain-of-identity controls, and long-term patient follow-up requirements. Unlike conventional biologics manufacturing, ATMP production often requires highly specialized cleanroom infrastructure, closed processing systems, cryogenic logistics, validated analytical methods, and quality systems aligned with Good Manufacturing Practice requirements across multiple jurisdictions. Regulatory agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency have established dedicated pathways and guidance for advanced therapies, reinforcing the need for CDMO partners with deep technical, regulatory, and quality expertise. The sector's strategic importance is also reinforced by the growing number of authorized cell and gene therapies, the expansion of clinical trial activity in oncology, rare diseases, immunology, and regenerative medicine, and the need to improve scalability, reproducibility, and cost efficiency without compromising safety or product identity.

Transformative Shifts in the ATMP CDMO Landscape

The ATMP CDMO landscape is undergoing transformative shifts as developers move from bespoke, manual, and research-grade processes toward industrialized, digitally controlled, and regulatory-ready manufacturing models. A major transition is the adoption of closed and automated manufacturing platforms that reduce contamination risk, improve process consistency, and support decentralized or point-of-care production models where clinically appropriate. Viral vector manufacturing remains a critical bottleneck because lentiviral, adeno-associated viral, and retroviral vectors require complex upstream and downstream workflows, stringent characterization, and scalable transfection or producer-cell technologies. At the same time, non-viral delivery systems, including lipid nanoparticles and transposon-based approaches, are gaining attention as developers seek alternatives that may improve scalability and reduce process constraints. Quality control is also shifting from end-product testing toward integrated process analytics, rapid microbiological methods, digital batch records, and real-time release-enabling strategies. Regulatory expectations are intensifying around comparability after process changes, analytical validation, potency assay relevance, raw material traceability, and donor-cell variability. These shifts are encouraging therapy developers to select CDMO partners earlier in development, particularly those capable of process development, GMP manufacturing, regulatory documentation, analytical lifecycle management, and global clinical supply coordination.

Cumulative Impact of Artificial Intelligence on ATMP CDMO Operations

Artificial intelligence is beginning to influence ATMP CDMO operations by improving process understanding, accelerating analytical interpretation, and strengthening quality decision-making. In cell therapy manufacturing, AI and machine learning can support pattern recognition across donor variability, culture conditions, cell expansion profiles, metabolite trends, and release-test outcomes. In gene therapy and vector production, AI-enabled models can assist with upstream parameter optimization, downstream yield improvement, impurity prediction, and batch deviation investigation. AI is also increasingly relevant in digital quality management through automated document review, anomaly detection in environmental monitoring, predictive maintenance of critical equipment, and faster assessment of batch records. For ATMPs, where every batch can be clinically meaningful and product comparability is complex, AI offers value by connecting manufacturing, analytical, clinical, and supply chain data into more coherent control strategies. However, adoption must be governed by validated systems, data integrity controls, explainability, cybersecurity safeguards, and regulatory alignment. The cumulative impact of AI is therefore not simply faster production; it is the potential to create more robust, transparent, and adaptive manufacturing ecosystems that improve reproducibility, reduce failure risk, and support evidence-based regulatory submissions.

Key Regional Insights Across the ATMP CDMO Ecosystem

Asia-Pacific is strengthening its position in ATMP CDMO activity through supportive regulatory modernization, expanding biomedical infrastructure, and growing clinical development in China, Japan, South Korea, India, Singapore, and Australia. Japan's regenerative medicine framework, South Korea's advanced biopharmaceutical manufacturing capabilities, China's large clinical research base, and Singapore's biomedical manufacturing ecosystem collectively support regional momentum. North America remains a highly mature ATMP CDMO region due to the concentration of clinical trials, authorized advanced therapies, academic medical centers, GMP infrastructure, and regulatory guidance from the FDA for human gene therapy, cellular therapy, and regenerative medicine products. Latin America is progressing more gradually, with Brazil and Mexico serving as important clinical research and biomanufacturing gateways, while regional challenges include uneven infrastructure, reimbursement constraints, and the need for harmonized regulatory capacity. Europe benefits from the EMA's centralized regulatory pathway for ATMPs, established GMP expertise, strong hospital-academic networks, and cross-border clinical research, with Germany, France, Italy, Spain, and the United Kingdom contributing to advanced therapy development and manufacturing capabilities. The Middle East is building interest through healthcare diversification strategies, clinical infrastructure investment, genomics programs, and medical innovation initiatives, particularly in Gulf economies seeking advanced biotechnology capabilities. Africa remains at an earlier stage, with opportunities tied to clinical research capacity building, biomanufacturing partnerships, workforce development, regulatory strengthening, and broader access to advanced biologics infrastructure.

Key Group Insights Shaping ATMP CDMO Strategies

ASEAN is emerging as an important growth corridor for ATMP-enabling services through Singapore's established biomedical manufacturing base, Thailand's medical research initiatives, Malaysia's biopharma development, and regional interest in cell therapy access, though capabilities vary significantly by country. The GCC is increasingly relevant as member states invest in healthcare transformation, genomics, specialty care, and biotechnology infrastructure, creating long-term potential for advanced therapy clinical adoption and localized manufacturing partnerships. The European Union provides one of the most structured regulatory environments for ATMPs through centralized authorization, GMP requirements, pharmacovigilance obligations, and scientific advice mechanisms, making it a key geography for multinational development strategies. BRICS countries present a diverse opportunity set: China and India offer large patient populations and expanding biomanufacturing capacity, Brazil and South Africa provide regional clinical and public health relevance, and Russia maintains scientific capabilities despite geopolitical and regulatory complexities. G7 countries remain influential because they host advanced regulatory agencies, leading research institutions, clinical trial networks, reimbursement decision-makers, and manufacturing expertise that shape global ATMP standards. NATO countries overlap substantially with major North American and European advanced therapy hubs, where supply chain resilience, critical healthcare infrastructure, biosecurity, and strategic manufacturing autonomy are increasingly important considerations for high-value biologics and advanced therapies.

Key Country Insights for ATMP CDMO Development

The United States is the most mature country-level environment for ATMP CDMO services, supported by FDA regulatory pathways, a deep clinical trial base, extensive translational research activity, and a broad network of GMP cell and gene therapy manufacturing capabilities. Canada contributes through strong academic hospitals, regenerative medicine networks, and clinical research infrastructure, while Mexico is gaining relevance for healthcare manufacturing and clinical development support in proximity to the U.S. Brazil is the leading Latin American country for advanced therapy development potential, supported by research institutions and biologics capabilities, although broader commercialization depends on regulatory, reimbursement, and infrastructure maturity. The United Kingdom remains a major ATMP hub due to coordinated cell and gene therapy initiatives, clinical manufacturing expertise, and innovation-focused regulatory engagement. Germany has deep GMP manufacturing competence, engineering strength, and advanced bioprocessing capabilities, while France combines hospital-based research, public biomedical investment, and cell therapy development infrastructure. Russia has scientific and clinical expertise in biotechnology, but international collaboration and supply chain integration are shaped by geopolitical and regulatory constraints. Italy and Spain are important European contributors through academic hospitals, clinical trial activity, and experience with cell therapy programs. China is rapidly expanding its ATMP ecosystem through high clinical research activity, domestic biomanufacturing investment, and regulatory evolution for cell and gene therapies. India is building capabilities through vaccine and biologics manufacturing heritage, clinical research capacity, and emerging cell and gene therapy initiatives. Japan is distinguished by its regenerative medicine regulatory framework and early conditional approval mechanisms for certain regenerative products. Australia supports ATMP development through strong clinical trial operations, hospital networks, and biomedical research, while South Korea is recognized for advanced biomanufacturing, cell therapy innovation, and government support for biopharmaceutical competitiveness.

Actionable Recommendations for ATMP CDMO Industry Leaders

Industry leaders should prioritize integrated ATMP CDMO strategies that connect process development, analytical validation, GMP manufacturing, regulatory planning, and clinical supply logistics from the earliest development stages. Developers should select partners with proven expertise in the specific modality, whether autologous cell therapy, allogeneic cell therapy, viral vector gene therapy, gene-edited cell therapy, tissue-engineered products, or combined ATMPs. Investment in closed processing, automation, digital batch records, electronic chain-of-identity and chain-of-custody systems, and cryogenic logistics can reduce operational risk and improve scalability. Quality strategies should emphasize potency assay development, raw material qualification, comparability protocols, contamination control, and data integrity. Organizations should also diversify critical inputs such as plasmids, viral vectors, cell culture media, single-use systems, and specialized reagents to strengthen supply continuity. Regulatory engagement should be proactive, with early scientific advice and alignment on manufacturing changes, release testing, long-term follow-up, and post-authorization commitments. Finally, leaders should build workforce capabilities in GMP aseptic operations, cell processing, vector analytics, quality assurance, regulatory affairs, and digital manufacturing, as talent constraints remain one of the most persistent barriers in the ATMP CDMO sector.

Research Methodology for ATMP CDMO Insights

This executive summary is developed using a verified secondary research approach grounded in publicly available regulatory, scientific, clinical, and industry sources. Inputs include guidance and public information from major regulatory authorities, peer-reviewed literature on cell and gene therapy manufacturing, clinical trial registry data, public health agency materials, academic publications, manufacturing standards, and documented industry practices in GMP advanced therapy production. The analysis applies qualitative triangulation across regulatory developments, clinical pipeline activity, manufacturing technology trends, supply chain considerations, and regional policy initiatives. The methodology intentionally excludes market sizing, market share estimation, revenue forecasting, or speculative projections. Instead, it focuses on evidence-backed indicators such as regulatory frameworks, authorized therapy categories, manufacturing requirements, infrastructure development, clinical research intensity, quality system needs, and technology adoption patterns. Regional, group, and country insights are synthesized into narrative assessments to support strategic understanding of ATMP CDMO dynamics while maintaining compliance with data integrity, traceability, and non-promotional content standards.

Conclusion: Strategic Outlook for ATMP CDMO Advancement

The Advanced Therapy Medicinal Products CDMO sector is becoming a critical enabler of next-generation healthcare as cell therapies, gene therapies, and regenerative medicine products move toward broader clinical and commercial use. The most competitive CDMO strategies will be built around modality-specific expertise, validated GMP infrastructure, strong analytical science, regulatory readiness, digital quality systems, and resilient supply chains. Regional momentum is strongest where clinical trial ecosystems, regulatory clarity, manufacturing investment, and specialized talent converge, while emerging regions are creating new opportunities through biotechnology capacity building and healthcare innovation programs. Artificial intelligence, automation, closed systems, and advanced analytics are expected to improve manufacturing control and quality performance, but their adoption must remain aligned with validation, compliance, and patient safety requirements. For developers, healthcare systems, and manufacturing partners, the central priority is clear: build scalable, compliant, and scientifically rigorous ATMP CDMO capabilities that can convert complex therapeutic innovation into reliable patient access.

Product Code: MRR-3A2E844FDCF6

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Advanced Therapy Medicinal Products CDMO Market, by Product Type

7.1. Introduction
7.2. Cell Therapy Products
- 7.2.1. Non-stem Cell Therapy
- 7.2.2. Stem Cell Therapy
7.3. Gene Therapy Products
- 7.3.1. Germline Therapy
- 7.3.2. Somatic Gene Therapy
7.4. Tissue Engineered Products

8. Advanced Therapy Medicinal Products CDMO Market, by Service Type

8.1. Introduction
8.2. Analytical Testing & Quality Control
8.3. Manufacturing Services
8.4. Process Development Services
8.5. Regulatory & Compliance Support

9. Advanced Therapy Medicinal Products CDMO Market, by Therapeutic Area

9.1. Introduction
9.2. Cardiology
9.3. Dermatology
9.4. Hematology
9.5. Neurology
9.6. Oncology

10. Advanced Therapy Medicinal Products CDMO Market, by End-User

10.1. Introduction
10.2. Academic & Research Institutes
10.3. Biotechnology Companies
10.4. Pharmaceutical Companies

11. Advanced Therapy Medicinal Products CDMO Market, by Region

11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa

12. Advanced Therapy Medicinal Products CDMO Market, by Group

12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO

13. Advanced Therapy Medicinal Products CDMO Market, by Country

13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea

14. Competitive Landscape

14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
- 14.3.1. Concentration Ratio (CR)
- 14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025

15. Company Profiles

15.1. AGC Biologics Inc.
15.2. Agilent Technologies, Inc.
15.3. Ajinomoto Bio-Pharma Services
15.4. Almac Group Ltd.
15.5. Biomay AG
15.6. BioSpring GmbH
15.7. Catalent, Inc.
15.8. Charles River Laboratories International, Inc.
15.9. CordenPharma International GmbH
15.10. Creative Biogene
15.11. Danaher Corporation
15.12. Eurofins Scientific SE
15.13. Evonik Industries AG
15.14. GenScript Biotech Corporation
15.15. Lonza Group Ltd.
15.16. Polypeptide Group AG
15.17. Recipharm AB
15.18. Rentschler Biopharma SE
15.19. Samsung Biologics Co., Ltd.
15.20. Sartorius AG
15.21. Siegfried AG
15.22. Syneos Health, Inc.
15.23. TFBS Bioscience Inc.
15.24. Touchlight Group
15.25. Univercells Group
15.26. WuXi AppTec Co., Ltd.

Product Code: MRR-3A2E844FDCF6

LIST OF FIGURES

FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

TABLE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CELL THERAPY PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CELL THERAPY PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CELL THERAPY PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NON-STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NON-STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NON-STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENE THERAPY PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENE THERAPY PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENE THERAPY PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GERMLINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GERMLINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GERMLINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SOMATIC GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SOMATIC GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SOMATIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANALYTICAL TESTING & QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANALYTICAL TESTING & QUALITY CONTROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANALYTICAL TESTING & QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 86. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 89. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 90. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 91. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 92. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 100. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 102. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 104. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 110. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 111. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 112. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 113. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 114. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 115. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 117. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 118. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 119. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 120. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 121. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 129. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 132. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 133. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 134. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 135. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 136. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 138. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 139. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 140. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 141. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 142. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 143. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 145. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 146. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 147. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 148. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 149. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 158. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 159. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 161. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 162. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 163. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 164. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 165. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 166. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 167. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 168. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 169. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 170. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 171. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 172. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 173. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 174. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 175. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 176. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 177. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 178. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 180. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 186. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 187. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 189. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 190. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 191. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 192. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 193. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 194. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 195. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 196. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 197. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 198. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 199. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 200. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 201. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 202. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 203. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 204. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 205. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 206. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 207. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 208. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 209. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 210. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 211. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 212. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 213. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 214. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 216. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 217. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 218. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 219. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 220. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 221. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 222. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 223. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 224. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 225. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 226. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 227. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 228. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 229. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 230. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 231. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 232. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 233. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 234. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 235. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 237. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 238. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 239. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 240. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 241. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 242. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 243. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 244. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 245. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 246. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 247. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 248. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 249. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 250. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 251. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 252. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
TABLE 253. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
TABLE 254. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 255. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 256. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
TABLE 257. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION